AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04576793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-MK6240
Description: MK-6240 measures a protein called in the brain. MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
Study NCT04576793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Florbetaben
Description: Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
Study NCT04576793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F-Florbetaben
Description: Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. florbetaben measures amyloid in the brain.
Study NCT03807310 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Counselling
Description: Counselling on healthy lifestyle (in particular physical activity, smoking cessation) and weight management by motivational interviewing
Study NCT01945840 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux en Y Gastric Bypass Surgery
Study NCT01945840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gut hormone infusion
Study NCT01945840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo infusion
Study NCT01945840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Very low calorie diet
Study NCT04576793 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
Study NCT04576793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumbar Puncture
Description: Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
Study NCT03506009 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Argatroban combined with rt-PA
Description: Argatroban as a 100-ug/kg bolus over 3 to 5 minutes was administered intravenously within 1 hour of the tPA bolus followed by a continuous Argatroban infusion of 1.0 ug/kg per minute for 48 hours adjusted to a target activated partial thromboplastin time of 1.75 X baseline (about 10%).
Study NCT03506009 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: Intravenous throbolysis with 0.9mg/kg rtPA.
Study NCT01904383 — intervention group
Intervention type: DRUG
Intervention: Trazenta
Description: 1 tablet of 5 mg Trazenta tablets once daily
Study NCT05233553 — intervention group
Intervention type: OTHER
Intervention: control of liver enzymes
Description: follow-up with clinical and laboratory measurements
Study NCT02102581 — intervention group
Intervention type: PROCEDURE
Intervention: short time tourniquet
Description: short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
Study NCT01097161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: speech therapy with the assistance of an acoustical analysis program
Description: Two weekly speech sessions realized on individual basis for three months period
Study NCT02768740 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone hemisuccinate
Description: In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Study NCT02894372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral spray 1
Description: Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
Study NCT02894372 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral spray 2
Description: Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
Study NCT02768740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone hemisuccinate
Description: In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
Study NCT03832998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 1
Description: Participants in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
Study NCT03832998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 2
Description: Participants in the low body-weight group at day 1 who are randomized to Dose Level 2 and participants in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
Study NCT03832998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab Dose 3
Description: Participants in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
Study NCT03832998 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching dose for erenumab dose 1, 2 and 3.
Study NCT01508585 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Based Cognitive Behavioral Therapy
Description: 6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
Study NCT03108079 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cystosure Urinary Access System
Description: 1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)
Study NCT03108079 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Foley Catheter
Description: 1. Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~2. Compare the fluid flow pattern during bladder drainage for~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)~3. Compare the 3D bladder wall anatomy after emptying the bladder with~   1. The traditional Foley catheter (Catheter A)~  2. The novel FDA approved Cystosure catheter (Catheter B)
Study NCT00252187 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B-type Natriuretic Peptide (BNP)
Description: BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
Study NCT00252187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo self-administered subcutaneously twice daily for 8 weeks.
Study NCT04160078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) Intervention
Description: * 1-hour session on sleep hygiene and 7-week follow up using a mindfulness app, an app that features guided meditation and can be used to assess adherence.~* Sleep log diary: self report of sleep records~* Wrist Actigraphy, to monitor sleep patterns. Participants will be instructed on wearing the sleep monitor (Spectrum, Philips Respironics, Murrysville, PA) on their non-dominant wrist for the next 7-weeks
Study NCT00440154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE5530
Study NCT00440154 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT00440154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ezetimibe
Study NCT00526773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telephone management plus a motivational intervention
Description: heart failure intervention
Study NCT00526773 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: telephone management with standard patient education
Description: heart failure intervention
Study NCT02330679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Desvenlafaxine
Description: The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
Study NCT02330679 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT04229303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole inhaled
Description: Part 1 (SAD): eligible subjects received a single ascending inhaled dose (5 mg, 10 mg, 20 mg, and 40 mg) of ZP-059 5mg capsules administered via dry powder inhaler (DPI) on the morning of Day 1.~Part 2 (MAD): eligible subjects received 2 (10mg twice daily \[BID\]) or 4 \[20mg BID\]) inhaled doses of ZP-059 5mg capsules administered via DPI BID for 9 days and once in the morning of Day 10, or 8 inhaled doses of ZP-059 5 mg capsules (40mg once daily \[QD\]) for 10 days. For QD dosing, subjects received QD doses of ZP-059 (at hour 0) on Days 1 to 10.~Part 3 (2-period crossover): eligible subjects received a 4 \[20mg BID\] inhaled doses of ZP-059 5mg capsules administered via DPI on the morning of Day 1 according to the crossover scheme of the study.~ZP-059 (inhaled voriconazole) was provided in clear, colorless size 3 hydroxypropylmethylcellulose hard capsules, which were individually and manually triggered by a breath actuated inhalation device (RS01 monodose inhaler).
Study NCT04229303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral voriconazole
Description: Part 3 (2-period crossover): eligible subjects received a single dose of oral voriconazole (200mg oral film-coated tablet, Vfend) on the morning of Day 1 according to the crossover scheme of the study.
Study NCT02181257 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Extracorporeal Photopheresis (ECP)
Description: Procedure:~ECP treatments will be performed using one of two Therakos systems. Both systems use the drug Methoxsalen
Study NCT02181257 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No intervention in the SOC / Retrospective Chart review.
Description: SOC Retrospective chart review similar to a control group
Study NCT03873779 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ System
Description: The CoolSculpting machine will be used to perform the treatments.
Study NCT04368585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr)
Description: Tebipenem pivoxil hydrobromide (TBPM-PI-HBr) 600 mg single-dose given orally.
Study NCT04368585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL)
Description: 20 mL aluminum hydroxide/magnesium hydroxide/simethicone (400 mg aluminum hydroxide/400 mg magnesium hydroxide/40 mg simethicone per 5 mL) oral suspension.
Study NCT04368585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg (1 x 40 mg capsule) omeprazole administered QD
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electroencephalography (EEG) multi-sensor
Description: Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Magnetoencephalography (MEG)
Description: Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Behavioral Measures
Description: The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reaction time measurement
Description: The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of physical performance
Description: The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrooculogram (EOG)
Description: In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electromyogram (EMG)
Description: In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram with 3 leads
Description: In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrodermogram (EDG)
Description: In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Consumption of O2 (VO2)
Description: In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
Study NCT03233282 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Production of CO2 (VCO2)
Description: In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
Study NCT03560622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multi-modality neuroimaging
Description: multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
Study NCT03560622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multi-modality neuroimaging
Description: multi-modality neuroimaging consists of structural imaging, diffusion tensor imaging (DTI), task-based functional MRI (t-fMRI), and resting state functional MRI (rs-fMRI).
Study NCT01492257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Intervention
Description: Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
Study NCT01020305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)~IUPAC name: (1R,2R,4S)-4-{(2R)-2-\[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido\[2,1-c\]\[1,4\]oxazacyclohentriacontin-3-yl\]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate
Study NCT01020305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casodex (bicalutamide)
Description: Casodex (bicalutamide) 50 mg/day PO
Study NCT04520035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: Carilizumab 200 mg, every 3 weeks, 2 cycles.Paclitaxel 175 mg / m2, D1, every 3 weeks, 2 cycles
Study NCT04520035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Cisplatin 75mg / m2 D1, conventional hydration for 3 days, every 3 weeks, 2 cycles
Study NCT04520035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy
Description: Neoadjuvant Chemotherapy
Study NCT02058810 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal high flow
Study NCT02058810 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional nasal oxygen
Study NCT04656522 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participatory Comic Intervention
Description: This participatory comic intervention promotes sexual violence prevention and post-rape care with refugee youth and health care providers. In 4-hour workshops, a customized comic book featuring eight sexual violence scenarios will be distributed. Each 1-page scenario speaks to a unique theme of sexual violence experiences among youth or post-rape care preferences. During the workshop participants will explore social, sexual, and psychological needs of youth in Bidi Bidi and practice ways of developing and maintaining healthy relationships (youth) as well as discuss post-rape care responses that attend to the needs and priorities of young refugees in Bidi Bidi who have experienced sexual violence (health care providers). Each workshop will include 20 participants and will be facilitated by trained staff from Real Medicine, Uganda. Further, each workshop will have at least 2 facilitators who are trained in the bystander model.
Study NCT01563471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: activated recombinant human factor VII
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
Study NCT01563471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: activated recombinant human factor VII
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
Study NCT01563471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
Study NCT01563471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
Study NCT02408406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Use PatientCareAnywhere system
Study NCT02408406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Use PatientCareAnywhere system
Study NCT02408406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Use PatientCareAnywhere system
Study NCT02408406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02548052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981278 0.03%
Description: GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
Study NCT02548052 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2981278 0.1%
Description: GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
Study NCT02408406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02408406 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02408406 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01555281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles